delta-Valerobetaine (DC12287) chemical structure
Chemical structureResearch use only
CAT. NO. DC12287Featured

delta-Valerobetaine

Pack size & price

USD
Ready-made solution
Total$700
We match the best price and quality on market.
Product overview

Description & Application

Delta-valerobetaine is a microbiome-derived metabolite used to investigate mitochondrial fatty-acid oxidation and diet-dependent obesity.

ParameterValue
Chemical Namedelta-Valerobetaine
CAS No.6778-33-2
Synonymsdelta-Valerobetaine; 5-(trimethylazaniumyl)pentanoate; 725A8L267W; delta-Valerobetaine-; 5-Aminovaleric acid betaine; 5-(Trimethylammonio)pentanoate; delta-Aminovaleric acid betaine; 5-(N-Trimethylamino)pentanoate; BDBM50008014; Q27896958; (4-Carboxybutyl)trimethylammonium hydroxide, inner salt; 1-Butanaminium, 4-carboxy-N,N,N-trimethyl-, inner salt; Ammonium, (4-carboxybutyl)trimethyl-, hydroxide, inner salt
FormulaC8H17NO2
M.Wt159.2261
SMILESC[N+](C)(C)CCCCC([O-])=O
PurityOn request
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Microbiome / carnitine metabolism · Literature evidence

Biological Activity

Delta-valerobetaine is a microbiome-derived metabolite used to investigate mitochondrial fatty-acid oxidation and diet-dependent obesity. δ-Valerobetaine lowered carnitine availability and mitochondrial long-chain acyl-CoA transport, reducing fatty-acid oxidation.

In Vitro

EndpointModel / conditions / sourceReported result
Metabolic mechanismCellular and biochemical metabolite studies. [1]δ-Valerobetaine lowered carnitine availability and mitochondrial long-chain acyl-CoA transport, reducing fatty-acid oxidation.

In Vivo

EndpointModel / conditions / sourceReported result
Germ-free modelMale C57BL/6 mice; 25 mg/kg intraperitoneally on weekdays for 6 weeks; chow or Western diet, n=5/group. [1], MethodsThe study tested interaction between the microbial metabolite and dietary context.
Conventional-mouse experiment50 mg/kg intraperitoneally on weekdays during an 8-week dietary study. [1]Western-diet conditions revealed increased visceral adiposity and hepatic steatosis; the effect was not reproduced uniformly on control chow.

Clinical / Human Evidence

EndpointModel / conditions / sourceReported result
Human associationHuman metabolomic observations. [1]Valerobetaine correlated with visceral adiposity. This association is not a randomized treatment effect.

Interpretation

Human correlation does not establish causation, and animal effects depended on diet.

Original studies

References

  1. Liu KH, et al. Microbial metabolite delta-valerobetaine is a diet-dependent obesogen. Nature metabolism (2021).

Product documentation

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

For additional quantities or product documentation, contact info@dcchemicals.com.

Related research products

Laropiprant chemical structureDC1009

Laropiprant

Laropiprant is a DP1 receptor antagonist for prostanoid signaling and platelet-function research. Its effects on platelet activation vary with agonist and concentration.

View activity & prices

Cart

Request quotation